Imidazolo-indazol-verbindungen als jak-hemmer

AT1896348TActive Publication Date: 2026-04-15THERAVANCE BIOPHARMA R&D IP LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
AT2022744598T
Authority / Receiving Office
AT · AT
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-06-25
Filing Date
2022-06-24
Publication Date
2026-04-15
Estimated Expiration
2042-06-24
Patent Text Reader

Abstract

Provided herein are compounds of formula (I): (I) and pharmaceutically-acceptable salts thereof, where A, W, X, Y and Z are defined in the specification. The compounds of formula (I) and pharmaceutically-acceptable salts thereof are Janus kinase (JAK) inhibitors. Also provided herein are pharmaceutical compositions comprising such compounds; and methods of using such compounds to treat, e.g., inflammatory and fibrotic diseases, including respiratory diseases.
Need to check novelty before this filing date? Find Prior Art